4152 Taiwan Liposome

TLC Highlights Findings in Abstract Accepted at Osteoarthritis Research Society International (OARSI) 2020 and Published in Osteoarthritis and Cartilage

TLC Highlights Findings in Abstract Accepted at Osteoarthritis Research Society International (OARSI) 2020 and Published in Osteoarthritis and Cartilage

Subgroup analyses of Phase II data confirm robustness of TLC599’s efficacy response of greater pain reductions than placebo through 24 weeks

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 18, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, today announced the publication of data from subgroup analyses from the Phase II clinical trial of in patients with osteoarthritis (OA) knee pain, which showed that the pattern of efficacy seen in the overall population, with greater reductions in pain with TLC599 than with placebo that sustained from Week 1 through Week 24, was remarkably consistent between the various subgroups. These findings were accepted as an abstract at 2020 and published in the journal ().

“We are happy to see that results of the subgroup analyses are consistent with our primary efficacy data,” said George Yeh, President of TLC. “These findings further substantiate the robustness of the potential therapeutic effects that TLC599 has in extensively alleviating pain and discomfort across different segments of the population with osteoarthritis, a disease that affects over 300 million adults worldwide.”

TLC599 is a sustained release formulation of dexamethasone sodium phosphate. In a primary intent-to-treat analysis of a Phase II multi-center, randomized, double-blind, placebo-controlled clinical trial, a single intraarticular dose of TLC599 12mg demonstrated significant and durable pain relief and improved function compared to placebo over 24 weeks in patients with knee OA pain. To examine the robustness of this efficacy response, the changes in pain from baseline in subgroups of the intent-to-treat population were analyzed. Subgroups were categorized based on gender (male or female), age (50-65 years or 65+ years), Kellgren-Lawrence (K-L Grade 2 or Grade 3), pain in one or both knees (unilateral or bilateral), baseline Visual Analog Scale (VAS) pain scores (<7 or ≥7), and baseline Western Ontario and McMaster Universities Index (WOMAC) pain scores (<1.2 or ≥1.2). The pattern of durable pain reduction with TLC599 was generally consistent across all subgroups, with drastic reductions in pain by the first visit (Week 1) which maintained through the 24-week duration of the trial.

About TLC599

Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. An in vivo toxicity study by staining of the cartilage showed TLC599 to be cartilage sparing compared to current treatments. In a Phase II clinical trial, a single injection of TLC599 resulted in statistically significant and clinically meaningful improvement in pain relief in both WOMAC and VAS scores over placebo for 24 weeks. Over half of the patients in the TLC599 group had a durable response, maintaining at least 30% pain reduction in both WOMAC and VAS pain scores at all visits through the 24 weeks. EXCELLENCE, a multi-center, randomized, double-blind, placebo- and active comparator-controlled pivotal Phase III clinical trial to evaluate the efficacy and safety of both single and repeated doses of TLC599, is ongoing.

About TLC

TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of a diverse, wholly owned portfolio of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™), including BioSeizer® sustained release technology and NanoX™ active drug loading technology, which are versatile in the choice of active pharmaceutical ingredients and scalable in manufacturing.

TLC Contact:
Dawn Chi
Corporate Communications
 
EN
18/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Taiwan Liposome

 PRESS RELEASE

Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Break...

Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology (ACR) Annual Meeting last week. TLC599 is an investigational therapy developed by TLC BioSciences for osteoarthritis knee pain. In his late-breaking oral presentation, Prof. Hunter provided background on osteoarthritis...

 PRESS RELEASE

TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Sessi...

TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) --  (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Selection Committee of the American College of Rheumatology (ACR) has accepted TLC's late-breaking abstract on TLC599 for oral presentation at ACR Con...

 PRESS RELEASE

TLC Announces TLC599 Agreement with Endo

TLC Announces TLC599 Agreement with Endo One of the largest deals seen in Taiwan’s biotech sector SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreement with (Nasdaq: ENDP) for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain. Under the terms of the ...

 PRESS RELEASE

TLC BioSciences Announces Publication of TLC599 Phase II Results in Ar...

TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy TLC599 reduces pain and improves function for up to 24 weeks, longer than existing intraarticular treatments, and significantly reduces oral medication use SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have...

 PRESS RELEASE

TLC Announces Voluntary Delisting and Deregistration of American Depos...

TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities will be issued in reliance upon the exemption from th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch